was diagnosed with bilateral pulmonar embolisms; I have extensive lung damage (infarctions); I have extensive lung damage (infarctions); I have many blood clots in my legs (DVT); last menstrual date 20Nov2020 / delivery date 19Aug2021; This is a spontaneous report received from a contactable consumer  via a regulatory authority. The reporter is the patient.  A 40 year-old female patient (pregnant) received bnt162b2 (BNT162B2), administered in arm right, administration date 10Apr2021 (Lot number: ER2613) at the age of 39 years as dose 2, single for covid-19 immunization. The patient's relevant medical history was not reported. Date of last menstrual period was 20Nov2020. The patient was 20 weeks pregnant at the time of exposure to bnt162b2. The patient was 39 weeks pregnant at the event onset. The patient was expected to deliver on 19Aug2021. There were no concomitant medications. Vaccination history included: Bnt162b2 (elaborated as dose administration date=18Mar2021, into the right arm, when the patient was 39 years old, for COVID-19 immunization). There were no known allergies.  The following information was reported: Deep vein thrombosis (hospitalization, life threatening) onset 2021, outcome "recovering" and described as "I have many blood clots in my legs (DVT)"; Pulmonary embolism (hospitalization, life threatening) with onset 19Aug2021, outcome "recovering", described as "was diagnosed with bilateral pulmonary embolisms"; Lung disorder (hospitalization, life threatening), Infarction (hospitalization, life threatening) all with onset 19Aug2021, outcome "recovering" and all described as "I have extensive lung damage (infarctions)"; Maternal exposure during pregnancy (non-serious) with onset 20Nov2021, outcome "recovering", described as "last menstrual date 20Nov2020 / delivery date 19Aug2021". The patient was hospitalized for deep vein thrombosis, pulmonary embolism, lung disorder, infarction (hospitalization duration: 4 day(s)). The events "I have many blood clots in my legs (dvt)", "was diagnosed with bilateral pulmonary embolisms", "I have extensive lung damage (infarctions)", and "last menstrual date 20nov2020 / delivery date 19aug2021" were evaluated at the physician office visit and emergency room visit. The patient underwent the following laboratory tests and procedures: sars-cov-2 test: (16Jul2021) negative. Therapeutic measures were taken as a result of deep vein thrombosis, pulmonary embolism, lung disorder, infarction.  Additional information: details were as follows: according to the patient,  she had many blood clots in her legs (DVT) since around the time of the vaccination. She noted that she never had blood clots before and they are atypical because she was only 40. The patient did not know precisely when they first appeared, because could not feel them, until one migrated to the lungs. She had excruciating chest pain on 19Aug2021. From then, the pain and trouble breathing got worse. I was diagnosed with bilateral pulmonary embolisms on 06Sep2021 in the emergency room. She had extensive lung damage (infarctions) and was admitted to the cardiac unit because of the strain on heart. The adverse event treatment included warfarin, among many other things  The lot number for the vaccine, BNT162B2, was not provided and will be requested during follow-up.